Position in RYTM
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$1,221
+$265 QoQ
Shares Held
11
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#285
of 299 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in RYTM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Whipplewood Advisors, LLC holds $18,301 across 8 Biotechnology names. RYTM ranks #6 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
4 | $3,711 | |
| 2 | ACAD |
Acadia Pharmaceuticals Inc
|
141 | $3,567 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
22 | $2,696 | |
| 4 | ABVX |
Abivax S.A.
|
19 | $2,531 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5 | $2,483 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
This page
|
11 | $1,221 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
15 | $1,189 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3 | $903 |
All Filings in RYTM
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,221 | 11 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $956 | 11 | Shares | Sole | 2026-04-30 | |
| 2025-06-30 | $695 | 11 | Shares | Other | 2025-07-31 | |
| 2025-03-31 | $688 | 13 | Shares | Sole | 2025-04-10 | |
| 2024-12-31 | $615 | 11 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||